PE20090299A1 - Antagonistas cxcr4 de peptido ciclicos - Google Patents
Antagonistas cxcr4 de peptido ciclicosInfo
- Publication number
- PE20090299A1 PE20090299A1 PE2008000868A PE2008000868A PE20090299A1 PE 20090299 A1 PE20090299 A1 PE 20090299A1 PE 2008000868 A PE2008000868 A PE 2008000868A PE 2008000868 A PE2008000868 A PE 2008000868A PE 20090299 A1 PE20090299 A1 PE 20090299A1
- Authority
- PE
- Peru
- Prior art keywords
- lys
- glu
- cxcr4 antagonists
- naphthylalanine
- gly
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
REFERIDA A UN PEPTIDO CICLIZADO POR LACTAMAS DE FORMULA (I), DONDE LA LACTAMA SE FORMA POR UN ENLACE AMIDA ENTRE EL GRUPO AMINO DE CADENA LATERAL DE X1 Y EL GRUPO CARBOXILO DE CADENA LATERAL DE X7; X1 Y X7 SON (D/L)Agl/Glu, Dab/Glu O Dap/Glu; R1 ESTA AUSENTE O ES ACETILO, BENZOILO O n-HEXANOILO; X1 ES Ala, 5-AMINOVALERILO, 4-ACIDO AMINO METILO, Asp, ENTRE OTROS; X3 ES Arg, Lys, Lys(iPr), Lys(Me2); X7 ES Asp, ACIDO 2,4-DIAMINOBUTIRICO, ACIDO 2,3-DIAMINO-PROPIONICO, ENTRE OTROS; X8 ES Arg, Gly, Lys, Orn, ENTRE OTROS; X9 ES Gly, 2-NAFTILALANINA, ENTRE OTROS; X10 ES 2-NAFTILALANINA O ESTA AUSENTE; R2 ES NH2 O NHEt. DICHOS COMPUESTOS SON ANTAGONISTAS CXCR4 Y SON UTILES EN EL TRATAMIENTO DE ARTRITIS REUMATICA, FIBROSIS PULMONAR, INFECCION POR VIH, ENTRE OTROS
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94080207P | 2007-05-30 | 2007-05-30 | |
US94099607P | 2007-05-31 | 2007-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20090299A1 true PE20090299A1 (es) | 2009-03-19 |
Family
ID=39831600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008000868A PE20090299A1 (es) | 2007-05-30 | 2008-05-20 | Antagonistas cxcr4 de peptido ciclicos |
Country Status (33)
Country | Link |
---|---|
US (3) | US7691813B2 (es) |
EP (2) | EP2160221B1 (es) |
JP (1) | JP5358564B2 (es) |
KR (2) | KR101319740B1 (es) |
CN (1) | CN101678213B (es) |
AR (1) | AR066648A1 (es) |
AT (1) | ATE516853T1 (es) |
AU (1) | AU2008260326B2 (es) |
BR (1) | BRPI0812134A2 (es) |
CA (1) | CA2688574C (es) |
CL (1) | CL2008001467A1 (es) |
CO (1) | CO6241137A2 (es) |
CR (1) | CR11105A (es) |
CY (1) | CY1111815T1 (es) |
DK (1) | DK2160221T3 (es) |
DO (1) | DOP2009000270A (es) |
EA (1) | EA017716B1 (es) |
GT (1) | GT200900304A (es) |
HK (1) | HK1141474A1 (es) |
HR (1) | HRP20110551T1 (es) |
IL (1) | IL201685A (es) |
JO (1) | JO2776B1 (es) |
MA (1) | MA31666B1 (es) |
MX (1) | MX2009012952A (es) |
MY (1) | MY149432A (es) |
NZ (1) | NZ580849A (es) |
PE (1) | PE20090299A1 (es) |
PL (1) | PL2160221T3 (es) |
PT (1) | PT2160221E (es) |
TN (1) | TN2009000496A1 (es) |
TW (1) | TWI423987B (es) |
WO (1) | WO2008150689A1 (es) |
ZA (1) | ZA200908345B (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2942798B1 (fr) | 2009-03-05 | 2011-04-08 | Centre Nat Rech Scient | Peptides utilisables pour le traitement de la leucemie lymphoide chronique |
IT1397901B1 (it) | 2010-01-26 | 2013-02-04 | Consiglio Nazionale Ricerche | Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico. |
WO2012118124A1 (ja) * | 2011-03-01 | 2012-09-07 | 国立大学法人京都大学 | 新規ケモカイン受容体拮抗剤 |
CN103703018B (zh) * | 2011-06-07 | 2016-10-26 | 波利弗尔股份公司 | 作为CXC4拮抗剂的β-发夹肽模拟物 |
WO2013044500A1 (zh) * | 2011-09-30 | 2013-04-04 | Cheng Yun | 丙型肝炎病毒免疫原性肽或其衍生物在预防或治疗关节炎中的应用 |
EP2771484A1 (en) | 2011-10-28 | 2014-09-03 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
EP2979991A1 (en) | 2014-07-31 | 2016-02-03 | Greif International Holding BV. | Multilayer material, fire protection mat with said multilayer material and transport and storage container assembly comprising said fire protection mat. |
EP3050574B1 (en) | 2015-01-28 | 2019-10-09 | Universite De Bordeaux | Use of plerixafor for treating and/or preventing acute exacerbations of chronic obstructive pulmonary disease |
WO2017176565A1 (en) | 2016-04-07 | 2017-10-12 | Eli Lilly And Company | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor |
JP7100639B2 (ja) * | 2016-09-06 | 2022-07-13 | メインライン バイオサエンシズ | Cxcr4アンタゴニストおよび使用方法 |
CN106841624B (zh) * | 2017-01-26 | 2019-02-22 | 庄磊靓 | 抗人cd4和抗人cd184单克隆抗体作为标志物的应用 |
US11123437B2 (en) * | 2017-09-05 | 2021-09-21 | Mainline Biosciences, Inc. | Selective CXCR4 binding peptide conjugate and methods for making and using the same |
EP3679053A4 (en) * | 2017-09-05 | 2021-10-27 | Mainline Biosciences | CXCR4 SELECTIVE BINDING CONJUGATE WITH HIGH AFFINITY AND METHOD OF USE |
US11771736B2 (en) * | 2017-12-21 | 2023-10-03 | Mainline Biosciences (Shanghai) Co., Ltd. | Composition comprising a therapeutic agent and a CXCR4 selective antagonist and methods for using the same |
JP2021165234A (ja) * | 2018-07-03 | 2021-10-14 | 富士フイルム富山化学株式会社 | Cxcr4結合性化合物もしくはその塩またはそれらと金属との錯体 |
CN112673015A (zh) | 2018-09-12 | 2021-04-16 | 慕尼黑工业大学 | 具有降低的物种选择性的cxcr4靶向诊断和治疗剂 |
WO2020053255A1 (en) | 2018-09-12 | 2020-03-19 | Technische Universität München | Therapeutic and diagnostic agents for cancer |
EP3956346A4 (en) * | 2019-04-18 | 2023-01-18 | Provincial Health Services Authority | NEW RADIOLABALED DIAGNOSTIC AND THERAPEUTIC COMPOUNDS TARGETING CXCR4 |
WO2021150258A1 (en) * | 2020-01-26 | 2021-07-29 | Mainline Biosciences Llc | Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same |
EP4269422A1 (en) * | 2020-12-25 | 2023-11-01 | Chugai Seiyaku Kabushiki Kaisha | Method for producing peptide compound containing n-substituted-amino acid residue |
EP4043041A1 (en) | 2021-02-15 | 2022-08-17 | Technische Universität München | Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof |
WO2023201435A1 (en) * | 2022-04-20 | 2023-10-26 | Provincial Health Services Authority | Cxcr4-targeting compounds, and methods of making and using the same |
CN115060901A (zh) * | 2022-06-21 | 2022-09-16 | 中国医学科学院基础医学研究所 | 苹果酸酶2在制备矽肺病或肺纤维化相关疾病诊断试剂或治疗药物中的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4391123B2 (ja) * | 2002-10-24 | 2009-12-24 | 株式会社オーファンリンク | 新規cxcr4アンタゴニスト |
CA2643744A1 (en) * | 2006-02-27 | 2007-08-30 | Technische Universitaet Muenchen | Cancer imaging and treatment |
-
2008
- 2008-05-20 PE PE2008000868A patent/PE20090299A1/es not_active Application Discontinuation
- 2008-05-20 NZ NZ580849A patent/NZ580849A/en not_active IP Right Cessation
- 2008-05-20 JO JO2008229A patent/JO2776B1/en active
- 2008-05-20 PL PL08769524T patent/PL2160221T3/pl unknown
- 2008-05-20 JP JP2010510418A patent/JP5358564B2/ja not_active Expired - Fee Related
- 2008-05-20 KR KR1020117026680A patent/KR101319740B1/ko not_active IP Right Cessation
- 2008-05-20 EA EA200971129A patent/EA017716B1/ru not_active IP Right Cessation
- 2008-05-20 KR KR1020097024829A patent/KR101169846B1/ko not_active IP Right Cessation
- 2008-05-20 EP EP08769524A patent/EP2160221B1/en active Active
- 2008-05-20 MY MYPI20095053A patent/MY149432A/en unknown
- 2008-05-20 PT PT08769524T patent/PT2160221E/pt unknown
- 2008-05-20 AT AT08769524T patent/ATE516853T1/de active
- 2008-05-20 CL CL2008001467A patent/CL2008001467A1/es unknown
- 2008-05-20 EP EP11172401A patent/EP2377579A1/en not_active Withdrawn
- 2008-05-20 AR ARP080102137A patent/AR066648A1/es unknown
- 2008-05-20 US US12/123,574 patent/US7691813B2/en not_active Ceased
- 2008-05-20 BR BRPI0812134-6A2A patent/BRPI0812134A2/pt not_active IP Right Cessation
- 2008-05-20 AU AU2008260326A patent/AU2008260326B2/en not_active Ceased
- 2008-05-20 DK DK08769524.3T patent/DK2160221T3/da active
- 2008-05-20 CA CA2688574A patent/CA2688574C/en not_active Expired - Fee Related
- 2008-05-20 MX MX2009012952A patent/MX2009012952A/es active IP Right Grant
- 2008-05-20 CN CN2008800178577A patent/CN101678213B/zh not_active Expired - Fee Related
- 2008-05-20 TW TW097118554A patent/TWI423987B/zh not_active IP Right Cessation
- 2008-05-20 WO PCT/US2008/064177 patent/WO2008150689A1/en active Application Filing
-
2009
- 2009-10-22 IL IL201685A patent/IL201685A/en not_active IP Right Cessation
- 2009-11-10 CR CR11105A patent/CR11105A/es not_active Application Discontinuation
- 2009-11-25 ZA ZA2009/08345A patent/ZA200908345B/en unknown
- 2009-11-26 TN TNP2009000496A patent/TN2009000496A1/fr unknown
- 2009-11-26 GT GT200900304A patent/GT200900304A/es unknown
- 2009-11-27 CO CO09135750A patent/CO6241137A2/es active IP Right Grant
- 2009-11-27 DO DO2009000270A patent/DOP2009000270A/es unknown
- 2009-12-21 MA MA32439A patent/MA31666B1/fr unknown
-
2010
- 2010-01-25 US US12/692,788 patent/US20100130409A1/en not_active Abandoned
- 2010-08-20 HK HK10107961.8A patent/HK1141474A1/xx not_active IP Right Cessation
- 2010-09-10 US US12/807,694 patent/USRE42274E1/en not_active Expired - Fee Related
-
2011
- 2011-07-25 HR HR20110551T patent/HRP20110551T1/hr unknown
- 2011-09-07 CY CY20111100861T patent/CY1111815T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20090299A1 (es) | Antagonistas cxcr4 de peptido ciclicos | |
ES2566830T3 (es) | Péptido capaz de extender la semivida de péptido de interés en plasma | |
ES2548767T3 (es) | Nuevos péptidos antimicrobianos | |
JP2010529957A5 (es) | ||
PE20140159A1 (es) | Coagonistas del receptor de glucagon/glp-1 | |
CY1113115T1 (el) | Πεπτιδια - αναστολεις συντηξης του ηiv με βελτιωμενες βιολογικες ιδιοτητες | |
DE69938064D1 (de) | Aminoterminal modifizierte parathyroidhormon (pth) analoge | |
UA100127C2 (ru) | Пептид cdh3 и лекарственное средство, содержащее его | |
Lohani et al. | Solid-phase synthesis and in vitro biological activity of a Thr4→ Ser4 analog of daptomycin | |
PE20231439A1 (es) | Proteinas f de hmpv estabilizadas por prefusion | |
HUP0300917A2 (hu) | Bradikardiakumok alkalmazása hipertrófiával társult miokardiális betegségek kezelésére és ezeket tartalmazó gyógyszerkészítmények | |
MXPA02000465A (es) | Derivados ciclopeptidicos como inhibidores de la integrina alfav beta6. | |
Tamamura et al. | Downsizing of an HIV–cell fusion inhibitor, T22 ([Tyr5, 12, Lys7]-Polyphemusin II), with the maintenance of anti-HIV activity and solution structure1 | |
JPWO2021070696A5 (es) | ||
Koizumi et al. | Structure–activity relationship of cyclic pentapeptide malformins as fibrinolysis enhancers | |
HUP0301396A2 (hu) | Integrin inhibitor hatású peptid- és peptidutánzó konjugátumok, azokat tartalmazó implantátumok és alkalmazásuk | |
NO20082127L (no) | Antagonister mot interaksjon av PF4 og Rantes | |
AU2016232361B2 (en) | Cyclic galanin-analogs and uses thereof | |
WO2007125142A8 (es) | Péptidos lineales antimicrobianos | |
Lee et al. | Synthesis and structure-function study about tenecin 1, an antibacterial protein from larvae of Tenebrio molitor | |
WO2008070049A8 (en) | Peptide and treatment for hiv-1 infection | |
NO20052525L (no) | Spleisevariant av humant hypofyseveksthormon | |
ATE529440T1 (de) | Biologisch aktives peptid und wirkstoff, der dieses enthält | |
Kanumuri et al. | Increased yield of high purity recombinant human brain natriuretic peptide by acid hydrolysis of short fusion partner in Escherichia coli | |
RS51950B (en) | CYCLIC PEPTIDE ANTAGONISTS CXCR4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |